Document:

Exhibit 10.1

 

March 28, 2022

 

Steve R. Martin

4503 Glencoe Avenue

Marina del Rey, CA 90292

 

Dear Steve:

 

This agreement (this “Agreement”)
replaces and supersedes the offer letter agreement between you and Armata Pharmaceuticals, Inc. (f/k/a AmpliPhi Biosciences Corporation)
(the “Company”) dated January 18, 2016, as amended on April 1, 2017 (the “Prior Agreement”)
and sets forth the terms of your continued employment with the Company in connection with your planned retirement as Chief Financial Officer.

 

1.            Continuing
Role. You agree to continue your employment with the Company on a full-time basis as Chief Financial
Officer and Principal Financial Officer through June 30, 2022, at which time you shall resign from those positions and all other
officer or director positions you may hold with the Company’s affiliates. During the period commencing on July 1, 2022 and
ending December 31, 2022 (the “Transition Period”) you shall continue your employment as a special advisor to
the new Principal Financial Officer of the Company. During the Transition Period, you will make reasonable efforts to be available to
provide the advisory and transition services with regard to the business and operations of the Company upon reasonable advance notice
as requested by the Chief Executive Officer or the Principal Financial Officer. Except upon the prior written consent of the Board of
Directors of the Company (the “Board”), you will not, during your employment with the Company, (a) accept or maintain
any other employment, or (b) engage, directly or indirectly, in any other business activity (whether or not pursued for pecuniary
advantage) that might interfere with your duties and responsibilities as a Company employee or create a conflict of interest with the
Company.

 

2.            Salary.
Your base salary for your services set forth in Section 1 above will continue to be paid at the annualized rate of $389,340, payable
on the Company’s regular payroll dates and subject to approved deductions and required withholdings.

 

3.            Bonus.
You will not be eligible to earn an annual performance bonus for the 2022 fiscal year.

 

4.            Equity
Awards. You shall not be eligible to receive grants of equity awards during the 2022 fiscal year.
However, your outstanding stock option and restricted share unit awards shall continue to vest, in accordance with their terms, for as
long as you continue to provide the services set forth in Section 1 above. Subject to and conditioned upon your continued employment
through December 31, 2022 and your satisfactory performance of the advisory and transition services set forth in Section 1 above,
one half of the outstanding and unvested Company stock options and restricted share units held by you as of the last day of the Transition
Period shall become fully vested as of that date, and all vested stock options held by you as of that date (including those that vest
hereunder) shall remain exercisable in full for their remaining 10-year term, provided that you sign and do not revoke a release of claims
on a form provided by the Company (the “Release”).

 

     

     

    

 

5.            Benefits.
You will be eligible to continue to participate in the benefits made generally available by the Company to its senior executives through
December 31, 2022, in accordance with the benefit plans established by the Company, and as may be amended from time to time in the
Company’s sole discretion; provided that you shall cease to accrue paid time off during the Transition Period.

 

6.            Termination
Obligations. The Company is an “at-will” employer. Accordingly, either you or the
Company may terminate the employment relationship at any time, with or without advance notice, and with or without cause.

 

a.            In
the event of a termination of your employment with the Company, by either party and regardless of the reasons, you shall be entitled to:
(i) any accrued but unpaid base salary and accrued but unused paid time off, which shall be paid in accordance with the Company's
customary payroll procedures and subject to all applicable deductions; (ii) reimbursement for unreimbursed business expenses properly
incurred by you, which shall be subject to and paid in accordance with the Company's expense reimbursement policy; (iii) such employee
benefits, if any, to which you may be entitled under applicable law, including COBRA; and (iv) your rights to outstanding stock options
and restricted share units in accordance with the terms, and subject to the conditions, of the 2016 Equity Incentive Plan (the “Equity
Plan”) and the applicable award agreements, as modified by Section 4 above.

 

b.            In
the event the Company terminates your employment prior to December 31, 2022 other than for “Cause” (as defined
in the Equity Plan), then in addition to the payments and benefits described in Section 6(a) above, and provided that you sign
and do not revoke a Release, you shall be entitled to the following payments and benefits (subject to applicable tax withholdings): (i) continued
payment of your base salary from the date of termination through December 31, 2022 (the “Severance Period”),
payable in regular installments in accordance with the Company’s normal payroll practices per the following terms: (x) the
installments shall commence to be paid on the first payroll date that occurs after the Release is received by the Company and becomes
effective and irrevocable in accordance with its terms, (y) the first installment shall include as a lump sum all payments (without
interest) that accrued from the termination date until such first payroll date, and (z) the remaining installments shall be paid
as otherwise scheduled for the remainder of the Severance Period, (ii) assuming that you elect COBRA coverage under the applicable
medical and dental plans of the Company, subsidized monthly COBRA premiums during the Severance Period, so that you will only be required
to pay the premiums applicable to continuing employees under those plans during that time; provided that such subsidy shall cease on
the date on which you become eligible for medical and dental coverage from a third party, and (iii) immediate vesting of your outstanding
equity awards, based on the number of shares that would have vested had you remained employed through the end of the Severance Period
and received the additional accelerated vesting (and extended exercise period) set forth in Section 4 above. The Company shall have
no further liability to pay you severance under any plan, agreement or arrangement maintained by the Company or its affiliates. For the
avoidance of doubt, the severance provisions of Section 8 of the Prior Agreement are replaced and superseded by this Section 6.

 

    2 

     

    

 

7.            Effect
on Prior Agreement. As noted above, this Agreement replaces and supersedes the Prior Agreement.
Notwithstanding the foregoing, the Proprietary Information and Invention Assignment Agreement between you and the Company shall remain
in full force and effect in accordance with its terms. For the avoidance of doubt, by signing below, and in consideration of the compensation
and benefits described in this letter, you hereby knowingly and voluntarily waive your right to terminate your employment with the Company
and its affiliates for “Good Reason” under the Prior Agreement as a result of the changes to your title, authorities, duties
or responsibilities as contemplated herein.

 

This Agreement shall inure
to the benefit of and be binding upon the Company and its successors and assigns.

 

Steve, we look forward to
your continuing role with the Company during 2022. Please sign and date this Agreement in the space provided below to acknowledge your
acceptance of the terms of this agreement.

 

Sincerely,

 

ARMATA PHARMACEUTICALS, INC.

 

 

	/s/ Brian Varnum	 
	Brian Varnum, Ph.D.	 
	Chief Executive Officer	 

 

ACCEPTED
AND AGREED:

 

 

	/s/ Steve R. Martin	 	March 28,
2022	 
	Steve R. Martin	 	Date	 

 

    3Exhibit 10.2

 

March 28, 2022

 

Erin Butler

4503 Glencoe Avenue

Marina del Rey, CA 90292

 

Dear Erin:

 

We are pleased to confirm our offer of continued
employment with Armata Pharmaceuticals, Inc. (the “Company”) in the position of Vice President of Finance and
Administration, effective April 1, 2022, on the terms set forth in this letter agreement (the “Agreement”).

 

1.            Position.
As Vice President of Finance and Administration, you will be responsible for managing the financial affairs of the Company and you will
report directly to the Chief Executive Officer of the Company. You agree to devote your full business time and attention to your work
for the Company. Except upon the prior written consent of the Board of the Directors of the Company (the “Board”),
you will not, during your employment with the Company, (i) accept or maintain any other employment, or (ii) engage, directly
or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that might interfere with your duties and
responsibilities as a Company employee or create a conflict of interest with the Company.

 

2.            Salary.
Effective as of April 1, 2022, your base salary will be paid at the annualized rate of $290,000 per year on the Company’s regular
payroll dates and subject to approved deductions and required withholdings. Your salary will be reviewed from time to time by the Board
or its compensation committee and may be adjusted in the sole discretion of the Board or its compensation committee.

 

3.            Bonus.
You will be eligible to earn an annual performance bonus based on achievement of Company performance objectives to be established by the
Board or its compensation committee and provided to you. Your annual target performance bonus will initially be equal to 30% of your base
salary, although the amount of any payment will be dependent upon actual performance as determined by the Board or its compensation committee.
You must be employed by the Company through the last day of the fiscal year for which bonuses are paid in order to be eligible to receive
a bonus. Your annual performance bonus, if any, shall be paid to you on or before March 15 of the year following the year to which
it relates. Your annual target performance bonus percentage is subject to modification from time to time in the discretion of the Board
or its compensation committee.

 

4.            Equity
Award. You will be granted an option under the Company’s 2016 Equity Incentive Plan (the
 “Plan”) to purchase 50,000 shares of the Company’s common stock (the “Option”). The Option
shall vest over time conditioned upon your continuous service to the Company in equal annual installments on the first four anniversaries
of the date of grant. The exercise price of the Option shall be the fair market value of the Company’s common stock on the date
of grant in accordance with the Plan and shall be subject to the terms and conditions of the Plan, stock option grant notice and option
agreement to be entered into between you and the Company.

 

     

     

    

 

5.            Benefits.
You will be eligible to continue to participate in the benefits made generally available by the Company to its senior executives, in accordance
with the benefit plans established by the Company, and as may be amended from time to time in the Company’s sole discretion.

 

6.            At-Will
Employment. The Company is an “at-will” employer. Accordingly, either you or the
Company may terminate the employment relationship at any time, with or without advance notice, and with or without cause.

 

7.            Termination.
Upon any termination of your employment, you will be deemed to have resigned, and you hereby resign, from all offices and directorships,
if any, then held with the Company or any subsidiary. In the event of termination of your employment with the Company, regardless of the
reasons for such termination, the Company shall pay your base salary and accrued but unused vacation up to and through the date of termination,
less applicable payroll and tax withholdings (the “Accrued Obligations”).

 

8.            Severance.
You shall be eligible for the severance benefits described in this Section 8.

 

a.            In
the event (i) the Company terminates your employment without Cause (as defined below and other than due to your death or disability),
or (ii) you terminate your employment for Good Reason (as defined below), and provided in either case of (i) or (ii) such
termination or resignation constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h),
without regard to any alternative definition thereunder, a “Separation from Service”) (such termination or resignation,
an “Involuntary Termination”), then, in addition to the Accrued Obligations, subject to your obligations below, you
shall be entitled to receive an amount equal to six (6) months of your then current base salary (ignoring any decrease in base salary
that forms the basis for Good Reason), less all applicable withholdings and deductions, paid on the schedule described below (the “Severance
Pay”).

 

b.            The
Severance Pay is conditional upon (i) your continuing to comply with your obligations under your PIIA (as defined in Section 11)
during the period of time in which you are receiving the Severance Pay; (ii) your delivering to the Company an executed separation
agreement and general release of claims in favor of the Company (the “Release”), in a form provided by the Company,
within the time period set forth therein, which becomes effective in accordance with its terms, which shall be no later than sixty (60)
days following your Separation from Service. The Severance Pay will be paid in equal installments on the Company’s regular payroll
schedule over the period outlined above following the date of your Separation from Service; provided, however, that no payments will
be made prior to the sixtieth (60th) day following your Separation from Service. On the sixtieth (60th) day following your Separation
from Service, the Company will pay you in a lump sum the amount of the Severance Pay that you would have received on or prior to such
date under the original schedule but for the delay while waiting for the sixtieth (60th) day, with the balance of the Severance Pay being
paid as originally scheduled.

 

    2 

     

    

 

c.            “Cause”
for purposes of your Severance Pay means (i) your gross negligence or willful failure substantially to perform your duties and responsibilities
to the Company or deliberate violation of a Company policy; (ii) your commission of any act of fraud, embezzlement or dishonesty
against the Company or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company;
(iii) your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom
you owe an obligation of nondisclosure as a result of your relationship with the Company; or (iv) your willful breach of any of your
obligations under any written agreement or covenant with the Company, including without limitation this Agreement and your PIIA (as defined
below).

 

d.            “Good
Reason” for purposes of your Severance Pay means the occurrence at any time of any of the following without your prior written
consent: (i) a material reduction in your authority, duties or responsibilities (other than a mere change in title following any
merger or consolidation of the Company with another entity); (ii) a material reduction in your base salary; or (iii) any willful
failure or willful breach by the Company of any of its material obligations under this Agreement. For purposes of this subsection, no
act, or failure to act, on the Company’s part shall be deemed “willful” unless done, or omitted to be done, by the Company
not in good faith and without reasonable belief that the Company’s act, or failure to act, was in the best interest of the Company.
In order to terminate your employment under this Agreement for Good Reason, you must (1) provide written notice to the Company within
ninety (90) days of the first occurrence of the events described above, (2) allow the Company at least thirty (30) days from such
receipt of such written notice to cure such event, and (3) if such event is not reasonably cured within such period, resign from
all position you then hold with the Company effective not later than the one-hundred eightieth (180th) day after the initial occurrence
of such event.

 

9.            Change
in Control. If your Involuntary Termination occurs within one (1) month prior to, or twelve
(12) months following a Change in Control (as defined in the Plan), the vesting of all of your outstanding equity awards (including the
Option) that are subject to time-based vesting requirements shall accelerate in full such that all such equity awards shall be deemed
fully vested as of the date of such Involuntary Termination (or Change in Control, if later).

 

10.            Taxes.
All amounts paid under this Agreement shall be paid less all applicable state and federal tax withholdings (if any) and any other withholdings
required by any applicable jurisdiction or authorized by you.

 

a.            Section 409A.
The Severance Pay provided in this Agreement is intended to qualify for an exemption from application of Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law
of similar effect (collectively “Section 409A”) or to comply with its requirements to the extent necessary to
avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. Each installment
of Severance Pay is a separate “payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i), and the Severance
Pay is intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4),
1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are not available and you are, upon Separation from Service, a “specified
employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under
Section 409A, the timing of the Severance Pay shall be delayed until the earlier of (i) six (6) months and one day after
your Separation from Service, or (ii) your death. Except to the minimum extent that payments must be delayed because you are a “specified
employee”, all amounts of Severance Pay will be paid as soon as practicable in accordance with the schedule provided herein and
in accordance with the Company’s normal payroll practices.

 

    3 

     

    

 

b.            Section 280G.
If any payment or benefit you will or may receive from the Company or otherwise (a “280G Payment”) would (i) constitute
a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject
to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment pursuant
to this Agreement or otherwise (a “Payment”) shall be equal to the Reduced Amount. The “Reduced Amount”
shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject
to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined
by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes,
and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater
economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment
is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence,
the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for
you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the
 “Pro Rata Reduction Method”).

 

Notwithstanding the foregoing,
if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to
Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro
Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:
(A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as
determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated
without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority,
Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before
Payments that are not deferred compensation within the meaning of Section 409A.

 

    4 

     

    

 

Unless you and the Company
agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day
prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations. If
the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change
of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder.
The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company
shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations,
together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your
right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested
by you or the Company.

 

If you receive a Payment for
which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 10(b) and the Internal
Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the
Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this this Section 10(b) so
that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined
pursuant to clause (y) in the first paragraph of this this Section 10(b), you shall have no obligation to return any portion
of the Payment pursuant to the preceding sentence.

 

11.            Other.
As a condition of your employment, you must continue to comply with the Company’s Proprietary Information and Invention Assignment
Agreement June 12, 2018 (“PIIA”), which (among other provisions) prohibits any unauthorized use or disclosure
of Company proprietary, confidential or trade secret information.

 

12.            Entire
Agreement. This Agreement, together with your PIIA, sets forth our entire agreement and understanding
regarding the terms of your employment with the Company and supersedes any prior representations or agreements, whether written or oral.
This Agreement may not be modified in any way except in a writing signed by the Company’s Chief Executive Offer (or another duly
authorized officer of the Company) upon due authorization by the Board or its compensation committee and you. It shall be governed by
California law, without regard to principles of conflicts of laws.

 

(Signatures are on the following page)

 

    5 

     

    

 

Sincerely,

 

 

	/s/ Brian Varnum	 
	Brian Varnum, Ph.D.	 
	Chief Executive Officer	 

 

 

ACCEPTED
AND AGREED:

 

 

	/s/ Erin Butler	 	March 28,
2022	 
	Erin Butler	 	Date	 

 

    6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]